Loading stock data…
BioLineRx Ltd. (BLRX)
$3.10-0.07 (-2.05%)
Market ClosedLast close Jun 29
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioLineRx Ltd. in the Healthcare sector is trading at $3.10 with a market capitalization of $15M. Wall Street consensus targets $17.50 (2 analysts), implying a +464.5% move over the next 12 months. The stock is currently 39% below its 52-week high of $5.06, remaining 0.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +464.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $477,000↑ | $194,000↓ | $427,000↑ | $304,000↑ | $255,000 |
| Gross Profit | $382,000↑ | $154,000↓ | $343,000↑ | $232,000↑ | $221,000 |
| Operating Income | -$3.00M↑ | -$3.39M↓ | -$2.21M↑ | -$2.30M↑ | -$2.39M |
| Net Income | -$1.60M↓ | -$1.39M↓ | -$977,000↑ | -$3.94M↓ | $5.13M |
Peer Comparison
JNJUNHPFE
Fundamentals
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$14.76M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.40%
Volume
Today's trading volume
10,427
Recent News
BioLine Rx Ltd (BLRX) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
BioLine Rx Ltd (BLRX) reports increased revenue and APHEXDA sales, while navigating a net loss and competitive pressures in the glioblastoma treatment landscape.
BioLineRx Shares Advance After First Patient Enrolled in GLIX1 Cancer Study (BLRX)
BioLineRx Ltd. (NASDAQ:BLRX) reported first-quarter 2026 financial results on Wednesday, shortly after announcing that the first patient had been dosed in its Phase 1/2a clinical study evaluating GLIX1 for the treatment of glioblastoma.
BioLine Rx Ltd (BLRX) Full Year 2025 Earnings Call Highlights: Navigating Challenges and ...
Despite a significant revenue drop, BioLine Rx Ltd (BLRX) focuses on innovative treatments and maintains a strong cash position to drive future growth.
BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
BioLine Rx Ltd (BLRX) reports reduced net loss and strategic developments in cancer treatment, bolstered by a strong cash position.
H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025
BioLineRx Ltd. (NASDAQ:BLRX) is among the best growth stocks to invest in for the next 5 years. H.C. Wainwright reaffirmed its Buy rating on BioLineRx Ltd. (NASDAQ:BLRX) while maintaining a price target of $26.00. This confidence follows the company’s participation in ASCO 2025, where the management presented full data from the pilot phase of its […]